Sanofi Revamps Commercial Ops, Prioritizes Fixed-Ratio Lantus-Lyxumia Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi plans to split its commercial organization into two units as the French drug giant starts to emerge from its patent cliff with a return to growth and a renewed focus on new diabetes therapies.